Board of Directors
Steve Tullman has served as Chairman of the Onspira Board of Directors since its inception in 2017 and is a co-founder of the company. Steve co-founded NeXeption, Inc. in May 2011 and NeXeption, LLC in August 2012, and currently serves as the managing partner of NeXeption, LLC. He previously served as Chairman, President and Chief Executive Officer of Ceptaris Therapeutics, Inc., from May 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Ltd, in September 2013. Steve served as Chairman of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. In 2005, he co-founded Ception Therapeutics, Inc. and served as its President and Chief Executive Officer until its acquisition by Cephalon, Inc. in 2010. In 2003, Steve co-founded Trigenesis Therapeutics, Inc., where he served as its Chief Business Officer (acquired by Dr. Reddy’s Laboratories Inc.). He began his career at SmithKline Beecham, where he held positions of increasing responsibility in finance, sales, marketing and research and development. He currently also serves as the Chairman of the Board of Directors of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), Ralexar Therapeutics, Inc., Velicept Therapeutics, Inc. and on the Boards of several other privately held companies. Steve received a BS in Accounting from Rutgers University.
Brian Lortie is a co-founder of Onspira Therapeutics and has served as President and Chief Executive Officer and as a member of the Board of Directors since its inception in 2017. During a career spanning more than 25 years of pharmaceutical leadership, Brian has built and led successful teams ranging from small, entrepreneurial startup ventures to large country operations and business units. He is a results-oriented leader with a record of achievement across all key areas including commercialization, clinical development, regulatory affairs, medical affairs, supply chain and business development. Prior to joining Onspira Therapeutics, Brian was President, Branded Pharmaceuticals at Endo Pharmaceuticals. He joined Endo in 2009 after spending much of his career with GlaxoSmithKline (GSK) and its predecessor companies. At GSK, his career progressed from sales to marketing in the US, then to Europe as Managing Director – Ireland. Returning to the US, Brian was Vice President and Business Unit Head for Diabetes, Urology and Anti-Infective Products, a portfolio which approached $3 billion in revenue. Brian returned to Europe for a role with the GSK Biologicals organization in Belgium as Vice President and Global Head – HPV Vaccine Franchise, where he held global responsibility for the development, registration and commercialization of GSK’s vaccine against HPV and cervical cancer. Following this, he returned to the US in a senior business development role where he led several product and business M&A activities. Brian holds a BA with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Roy Clifford Levitt, MD
Roy Levitt, MD, has more than 35 years of experience as a physician-scientist and 22 years in pharmaceuticals development including leadership in development stage and global commercial biopharmaceuticals. Roy is co-founder of Onspira Therapeutics and serves as its Chief Scientific Officer and as a member of the Board of Directors. He is a board-certified anesthesiologist, internist and practicing pain specialist with over 125 peer-reviewed publications. He is also a serial inventor and entrepreneur with more than 20 issued patents. Prior to joining Onspira, he created and led multiple biopharmaceutical companies and held various positions of increasing responsibility including Medical Director, Commercial Operations, CSL Behring; and Chief Executive Officer, President and board member of Genera Corporation. Roy earned a BS in chemistry and an MD from the University of Maryland. He completed graduate and advanced training in anesthesiology, genetics and internal medicine at The Johns Hopkins Medical Institutions; and as an inter-institutes medical genetics fellow at the National Institutes of Health.
Director and Board Secretary
Paul Barone has more than 30 years of experience in business development, marketing, law and finance in the pharmaceutical and biotech industries. He is a co-founder of Onspira Therapeutics and serves as an advisor and a member of the Board of Directors. Paul led the Business Development function for Heron Therapeutics, Celldex Therapeutics and EUSA Pharma and managed out- and in-licensing processes culminating in numerous transactions while also providing in-house counsel. He was a founding member of Reliant Pharmaceuticals, co-founded Essential Pharmaceuticals (sold in July 2017 for a six MOIC), and co-founded Freyeur & Trogue, an investment bank and consultancy. Paul began his career at Merck & Co. and held positions of increasing responsibility including Director of Strategic Planning & Business Development. Paul received his MBA from Fairleigh Dickinson University and his JD from Seton Hall University. He is also a CPA.